These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24373236)

  • 21. GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity.
    Fyfe MC; McCormack JG; Overton HA; Procter MJ; Reynet C
    Expert Opin Drug Discov; 2008 Apr; 3(4):403-13. PubMed ID: 23489096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119.
    Kang SU
    Drug Discov Today; 2013 Dec; 18(23-24):1309-15. PubMed ID: 24060477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates.
    Hryciw DH; Patten RK; Rodgers RJ; Proietto J; Hutchinson DS; McAinch AJ
    Expert Opin Investig Drugs; 2024 Mar; 33(3):183-190. PubMed ID: 38372052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. G-protein-coupled receptors (GPCRs) in the treatment of diabetes: Current view and future perspectives.
    Sebastiani G; Ceccarelli E; Castagna MG; Dotta F
    Best Pract Res Clin Endocrinol Metab; 2018 Apr; 32(2):201-213. PubMed ID: 29678286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease.
    Zhao J; Zhao Y; Hu Y; Peng J
    Cell Mol Biol Lett; 2021 Jul; 26(1):32. PubMed ID: 34233623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus.
    Riddy DM; Delerive P; Summers RJ; Sexton PM; Langmead CJ
    Pharmacol Rev; 2018 Jan; 70(1):39-67. PubMed ID: 29233848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
    Li Z; Xu X; Huang W; Qian H
    Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Free fatty acid (FFA) and hydroxy carboxylic acid (HCA) receptors.
    Offermanns S
    Annu Rev Pharmacol Toxicol; 2014; 54():407-34. PubMed ID: 24160702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GPR119 regulates genetic markers of fatty acid oxidation in cultured skeletal muscle myotubes.
    Cornall LM; Mathai ML; Hryciw DH; Simcocks AC; O'Brien PE; Wentworth JM; McAinch AJ
    Mol Cell Endocrinol; 2013 Jan; 365(1):108-18. PubMed ID: 23069642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease.
    Pols TW; Auwerx J; Schoonjans K
    Gastroenterol Clin Biol; 2010; 34(4-5):270-3. PubMed ID: 20444564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Free fatty acid receptor 1 as a novel therapeutic target for type 2 diabetes mellitus-current status.
    Eleazu C; Charles A; Eleazu K; Achi N
    Chem Biol Interact; 2018 Jun; 289():32-39. PubMed ID: 29704509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
    Chen C; Li H; Long YQ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The role of pharmacology to produce firuglipel (DS-8500a), an orally available GPR119 agonist for type 2 diabetes mellitus].
    Matsumoto K; Yoshitomi T; Shimada T
    Nihon Yakurigaku Zasshi; 2018; 152(3):119-124. PubMed ID: 30185729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.
    Semple G; Lehmann J; Wong A; Ren A; Bruce M; Shin YJ; Sage CR; Morgan M; Chen WC; Sebring K; Chu ZL; Leonard JN; Al-Shamma H; Grottick AJ; Du F; Liang Y; Demarest K; Jones RM
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1750-5. PubMed ID: 22264481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of GPR119 receptor activity with endocannabinoid-like lipids.
    Syed SK; Bui HH; Beavers LS; Farb TB; Ficorilli J; Chesterfield AK; Kuo MS; Bokvist K; Barrett DG; Efanov AM
    Am J Physiol Endocrinol Metab; 2012 Dec; 303(12):E1469-78. PubMed ID: 23074242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cytoprotective effects of oleoylethanolamide in insulin-secreting cells do not require activation of GPR119.
    Stone VM; Dhayal S; Smith DM; Lenaghan C; Brocklehurst KJ; Morgan NG
    Br J Pharmacol; 2012 Apr; 165(8):2758-70. PubMed ID: 22029844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.
    Han S; Narayanan S; Kim SH; Calderon I; Zhu X; Kawasaki A; Yue D; Lehmann J; Wong A; Buzard DJ; Semple G; Carroll C; Chu ZL; Al-Sharmma H; Shu HH; Tung SF; Unett DJ; Behan DP; Yoon WH; Morgan M; Usmani KA; Chen C; Sadeque A; Leonard JN; Jones RM
    Bioorg Med Chem Lett; 2015 Aug; 25(15):3034-8. PubMed ID: 26048791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2-OMe-lysophosphatidylcholine analogues are GPR119 ligands and activate insulin secretion from βTC-3 pancreatic cells: Evaluation of structure-dependent biological activity.
    Drzazga A; Sowińska A; Krzemińska A; Okruszek A; Paneth P; Koziołkiewicz M; Gendaszewska-Darmach E
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Jan; 1863(1):91-103. PubMed ID: 29079451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.